Induction of Antigen Specific Immunological Tolerance Using Inducible Pluripotent Stem Cell Derived Veto Cells
US-2024374723-A1 · Nov 14, 2024 · US
Use of anti-cancer cell composition for treatment of head and neck cancer, which is intended to be administered to nutrient artery of tumor
US9101558B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9101558-B2 |
| Application number | US-67992308-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 26, 2008 |
| Priority date | Sep 26, 2007 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
To provide a method of efficiently delivering cells having an anti-tumor activity to tumor tissues to evoke a stronger anti-tumor reaction, and a method of providing a more effective tumor regression effect, both in a cellular immunotherapy for cancer utilizing cells having an anti-tumor activity or antigen presenting cells for activating cells capable of exhibiting an anti-tumor activity. Provided are: a method of treating head and neck cancer, comprising administering an anti-cancer cell composition containing NKT cells activated in vitro with an NKT cell ligand into the tumor-feeding artery, and administering an NKT cell-stimulating agent containing antigen presenting cells treated with an NKT cell ligand through the upper respiratory tract mucous membrane; a use, in anti-cancer treatment of head and neck region, of the anti-cancer cell composition and the NKT cell-stimulating agent; a kit comprising the anti-cancer cell composition and the NKT cell-stimulating agent; and the anti-cancer cell composition.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating head and neck cancer, comprising obtaining blood components from a head and neck cancer patient diagnosed with head and neck cancer, administering an anti-cancer cell composition containing NKT cells obtained from the blood components obtained from the patient and activated in vitro with α-galactosylceramide in an administration number of 1 ×10 7 cells to 1 ×10 9 cells into a tumor-feeding artery of a head and neck cancer 14 da…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9101558B2 cover?
- To provide a method of efficiently delivering cells having an anti-tumor activity to tumor tissues to evoke a stronger anti-tumor reaction, and a method of providing a more effective tumor regression effect, both in a cellular immunotherapy for cancer utilizing cells having an anti-tumor activity or antigen presenting cells for activating cells capable of exhibiting an anti-tumor activity. Prov…
- Who is the assignee on this patent?
- Taniguchi Masaru, Horiguchi Shigetoshi, Okamoto Yoshitaka, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0639. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).